Two Roads to Fast Clinical Trials, and the US Takes Neither

Short summary

HHS launches Operation TrialBlazer to accelerate US clinical trials amid China's strategic biotech expansion, including streamlined regulatory pathways and sustained infrastructure investment. The US faces two possible routes forward—accelerated approval or alternative trial designs—but is pursuing neither decisively. This regulatory gap threatens US competitiveness in biotechnology as China gains ground.

• •China has made biotech a strategic priority with government-backed regulatory streamlining and infrastructure investment
• •HHS launched Operation TrialBlazer but the US lacks clear commitment to either accelerated approval or novel trial designs
• •The regulatory gap creates a competitive disadvantage for US biotech innovation

Generated with AI, which can make mistakes.